This clinical trial was designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of a single dose of PTI-202 in healthy volunteers. Pain Therapeutics believes the results also indicate PTI-202 is safe and well-tolerated and its release profile appears well-suited for use with a chronic pain population. There were no unexpected adverse events in this trial.
“These results in healthy volunteers nicely recapitulate what we previously observed in animal studies and provide further evidence that the underlying abuse-resistant platform can be applied across different opioid painkillers.” said Remi Barbier, president and CEO.
PTI-202 is intended to meet the needs of physicians who appropriately prescribe opioid painkillers and who seek to minimize the risks of drug diversion, abuse or accidental patient misuse.